Anti-ERCC1 Antibody

ERCC1 (Excision Repair Cross-Complementation Group 1) is a key DNA repair protein that forms a heterodimeric endonuclease with XPF/ERCC4, catalyzing the 5' incision step during nucleotide excision repair (NER). The complex also participates in DNA interstrand crosslink repair, homologous recombination, and telomere maintenance, making ERCC1 a focus of research in genome stability, aging, and cancer biology.

Clinically, ERCC1 expression levels are studied as a predictive biomarker for platinum-based chemotherapy response, including cisplatin, carboplatin, and oxaliplatin, in non-small cell lung cancer, ovarian cancer, colorectal cancer, and other solid tumors, where low ERCC1 expression is often associated with improved platinum sensitivity.

This polyclonal antibody from Antibodies.com is raised in rabbit, supplied unconjugated in a 100 µl volume, and validated for Western blot, immunohistochemistry, and immunofluorescence on human samples. The unconjugated format gives researchers flexibility to pair it with their preferred secondary antibody and detection chemistry, supporting work in DNA damage response, chemoresistance studies, and tumor biology.